Written Authority Required Drugs 012-63060000

Term

Description

abatacept

Abatacept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, abatacept is subsidised for the treatment of rheumatoid arthritis.

adalimumab

Adalimumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, adalimumab is subsidised for the treatment of:

• ankylosing spondylitis
• Crohn's disease:
• adult
• paediatric
• enthesitis/spondylitis juvenile idiopathic arthritis
• fistulising Crohn's disease
• hidradenitis suppurativa
• juvenile idiopathic arthritis
• non-infectious uveitis
• psoriatic arthritis
• rheumatoid arthritis
• severe chronic plaque psoriasis:
• adult
• ulcerative colitis:
• adult
• paediatric

aflibercept

Aflibercept is a Section 85 listed pharmaceutical benefit.

Providing the patient meets specific restriction criteria, aflibercept is subsidised for the treatment of:

• diabetic macular oedema
• retinal vein occlusion with macular oedema
• subfoveal choroidal neovascularisation due to:
• age related macular degeneration
• pathologic myopia
• other causes

ambrisentan

Ambrisentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, ambrisentan is subsidised for the treatment of pulmonary arterial hypertension.

anifrolumab

Anifrolumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, anifrolumab is subsidised for the treatment of systemic lupus erythematosus.

armodafinil

Armodafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, armodafinil is subsidised for the treatment of narcolepsy.

asciminib

Asciminib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, asciminib is subsidised for the treatment of chronic myeloid leukaemia.

avatrombopag

Avatrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, avatrombopag is subsidised for the treatment of idiopathic thrombocytopenic purpura.

azacitidine

Azacitidine is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, azacitidine is subsidised for the treatment of:

• myelodysplastic syndrome
• chronic myelomonocytic leukaemia
• acute myeloid leukaemia

baricitinib

Baricitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, baricitinib is subsidised for the treatment of rheumatoid arthritis.

benralizumab

Benralizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, benralizumab is subsidised for the treatment of:

• severe asthma:
• adult
• adolescent

bimekizumab

Bimekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, bimekizumab is subsidised for the treatment of:

• non-radiographic axial spondyloarthritis
• ankylosing spondylitis
• hidradenitis suppurativa
• psoriatic arthritis
• severe chronic plaque psoriasis:
• adult

blinatumomab

Blinatumomab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, blinatumomab is subsidised for the treatment of acute lymphoblastic leukaemia.

bosentan monohydrate

Bosentan monohydrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, bosentan monohydrate is subsidised for the treatment of pulmonary arterial hypertension.

brentuximab vedotin

Brentuximab vedotin is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, brentuximab is subsidised for the treatment of:

• CD30 positive systemic anaplastic large cell lymphoma
• relapsed or refractory Hodgkin lymphoma
• cutaneous T-cell lymphoma
• peripheral T-cell lymphoma
• stage III or IV CD30 positive Hodgkin lymphoma

brolucizumab

Brolucizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, brolucizumab is subsidised for the treatment of age related macular degeneration (AMD).

burosumab

Burosumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, burosumab is subsidised for the treatment of X-linked hypophosphataemia (XLH).

certolizumab pegol

Certolizumab pegol is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, certolizumab is subsidised for the treatment of:

• rheumatoid arthritis
• ankylosing spondylitis
• psoriatic arthritis
• non-radiographic axial spondyloarthritis

crizotinib

Crizotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, crizotinib is subsidised for the treatment of Stage IIIB or Stage IV non-small-cell lung cancer.

daratumumab

Daratumumab is a Section 85 and 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, daratumumab is subsidised for the treatment of untreated multiple myeloma.

dasatinib

Dasatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, dasatinib is subsidised for the treatment of:

• acute lymphoblastic leukaemia
• chronic myeloid leukaemia

daunorubicin+cytarabine

Daunorubicin+cytarabine is listed under Section 100 – Efficient funding of chemotherapy arrangements and administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, daunorubicin+cytarabine is subsidised for the treatment of acute myeloid leukaemia.

decitabine+cedazuridine

Decitabine+cedazuridine is a Section 85 listed pharmaceutical benefit.

Providing the patient meets specific restriction criteria, decitabine+cedazuridine is subsidised for the treatment of:

• acute myeloid leukaemia
• chronic myelomonocytic leukaemia
• myelodysplastic syndrome

dexamethasone implant

Dexamethasone is a Section 85 listed pharmaceutical benefit.

Providing the patient meets the specific restriction criteria, dexamethasone implant is subsidised for the treatment of:

• diabetic macular oedema
• retinal vein occlusion macular oedema

difelikefalin

Difelikefalin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, difelikefalin is subsidised for the treatment of chronic kidney disease-associated pruritus.

dupilumab

Dupilumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, dupilumab is subsidised for the treatment of severe asthma.

eculizumab

Eculizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, eculizumab is subsidised for the treatment of:

• atypical haemolytic uraemic syndrome
• paroxysmal nocturnal haemoglobinuria

eflornithine

Eflornithine is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, eflornithine is subsidised for the treatment of high-risk neuroblastoma.

elexacaftor+tezacaftor+ivacaftor

Elexacaftor+tezacaftor+ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, elexacaftor+tezacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis.

elotuzumab

Elotuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, elotuzumab is subsidised for the treatment of multiple myeloma.

eltrombopag

Eltrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, eltrombopag is subsidised for the treatment of:

• idiopathic thrombocytopenic purpura
• severe aplastic anaemia

entrectinib

Entrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, entrectinib is subsidised for the treatment of Stage IIIB or Stage IV non-small-cell lung cancer.

epoprostenol sodium

Epoprostenol sodium is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, epoprostenol sodium is subsidised for the treatment of pulmonary arterial hypertension.

etanercept

Etanercept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, etanercept is subsidised for the treatment of:

• ankylosing spondylitis
• juvenile idiopathic arthritis
• psoriatic arthritis
• rheumatoid arthritis
• severe chronic plaque psoriasis:
• adults
• paediatric

etrasimod

Etrasimod is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, etrasimod is subsidised for the treatment of ulcerative colitis.

faricimab

Faricimab is a Section 85 listed pharmaceutical benefit.

Providing the patient meets specific restriction criteria, faricimab is subsidised for the treatment of:

• diabetic macular oedema
• branch retinal vein occlusion with macular oedema
• central retinal vein occlusion with macular oedema
• subfoveal choroidal neovascularisation due to age related macular degeneration

golimumab

Golimumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, golimumab is subsidised for the treatment of:

• ankylosing spondylitis
• ulcerative colitis:
• adult
• psoriatic arthritis
• rheumatoid arthritis
• non-radiographic axial spondyloarthritis

guselkumab

guselkumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, guselkumab is subsidised for the treatment of:

• Psoriatic arthritis
• Severe chronic plaque psoriasis:
• adult

iloprost trometamol

Iloprost trometamol is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, iloprost trometamol is subsidised for the treatment of pulmonary arterial hypertension.

imatinib

Imatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, imatinib is an agent subsidised for the treatment of:

• chronic myeloid leukaemia
• gastrointestinal stromal tumour
• acute lymphoblastic leukaemia

infliximab

Infliximab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, infliximab is subsidised for the treatment of:

• ankylosing spondylitis
• Crohn's disease:
• adults
• paediatric (Section 100 only)
• fistulising Crohn's disease
• psoriatic arthritis
• rheumatoid arthritis
• severe chronic plaque psoriasis:
• adults
• ulcerative colitis:
• adult
• paediatric (Section 100 only)

Inotuzumab ozogamicin

Inotuzumab ozogamicin is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, inotuzumab ozogamicin is subsidised for the treatment of acute lymphoblastic leukaemia.

iptacopan (Fabhalta®)

Iptacopan is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, iptacopan is subsidised for the treatment of paroxysmal nocturnal haemoglobinuria.

ivacaftor

Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, ivacaftor is subsidised for the treatment of cystic fibrosis.

ixekizumab

Ixekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, ixekizumab is subsidised for the treatment of:

• ankylosing spondylitis
• psoriatic arthritis
• severe chronic plaque psoriasis:
• adult

lanadelumab

Lanadelumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, lanadelumab is subsidised for the treatment of hereditary angioedema type 1 or 2.

lapatinib

Lapatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, lapatinib is subsidised for the treatment of metastatic breast cancer.

larotrectinib

Larotrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, larotrectinib is subsidised for the treatment of solid tumours that are confirmed to be neurotrophic tropomyosin receptor kinase (NTRK) gene fusion positive.

lenalidomide

Lenalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, lenalidomide is subsidised for the treatment of:

• multiple myeloma
• myelodysplastic syndrome

lumacaftor+ivacaftor

Lumacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, lumacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis.

lumasiran

Lumasiran is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, lumasiran is subsidised for the treatment of primary hyperoxaluria type 1.

macitentan

Macitentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, macitentan is subsidised for the treatment of pulmonary arterial hypertension.

macitentan+tadalafil

Macitentan+tadalafil is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, macitentan+tadalafil is subsidised for the continuing treatment of pulmonary arterial hypertension.

mavacamten

Mavacamten is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, mavacamten is subsidised for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

mecasermin

Mecasermin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, mecasermin is subsidised for the treatment of Severe growth failure with primary insulin-like growth factor-1 deficiency.

mepolizumab

Mepolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, mepolizumab is subsidised for the treatment of:

• severe asthma:
• adult
• adolescent
• chronic rhinosinusitis with nasal polyps (CRSwNP)

midostaurin

Midostaurin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, midostaurin is subsidised for the treatment of acute myeloid leukaemia.

migalastat

Migalastat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, migalastat is subsidised for the treatment of Fabry disease.

modafinil

Modafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, modafinil is subsidised for the treatment of narcolepsy.

nilotinib

Nilotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, nilotinib is subsidised for the treatment of chronic myeloid leukaemia.

nintedanib

Nintedanib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, nintedanib is subsidised for the treatment of:

• idiopathic pulmonary fibrosis
• progressive fibrosing interstitial lung disease

nusinersen

Nusinersen is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, nusinersen is subsidised for the treatment of spinal muscular atrophy.

odevixibat

Odevixibat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, odevixibat is subsidised for the treatment of progressive familial intrahepatic cholestasis disease.

omalizumab

Omalizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, omalizumab is subsidised for the treatment of:

• severe asthma
• chronic spontaneous urticaria

onasemnogene abeparvovec

Onasemnogene abeparvovec is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public hospital authority required.

Providing the patient meets specific restriction criteria, onasemnogene abeparvovec is subsidised for the treatment of spinal muscular atrophy.

ozanimod

Ozanimod is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ozanimod is subsidised for the treatment of ulcerative colitis (adult).

palovarotene

Palovarotene is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, palovarotene is subsidised for the treatment of fibrodysplasia ossificans progressiva.

pasireotide

Pasireotide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority is required.

Providing the patient meets specific restriction criteria, pasireotide is subsidised for the treatment of acromegaly.

patisiran

Patisiran is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority is required.

Providing the patient meets specific restriction criteria, patisiran is subsidised for the treatment of hereditary transthyretin amyloidosis.

pegcetacoplan

Pegcetacoplan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, pegcetacoplan is subsidised for the treatment of paroxysmal nocturnal haemoglobinuria.

pegvisomant

Pegvisomant is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority is required.

Providing the patient meets specific restriction criteria, pegvisomant is subsidised for the treatment of acromegaly.

pertuzumab

Pertuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, pertuzumab is subsidised for the treatment of metastatic breast cancer.

pirfenidone

Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, pirfenidone is subsidised for the treatment of idiopathic pulmonary fibrosis.

polylactic acid

Polylactic acid is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, polylactic acid is subsidised for the treatment of severe facial lipoatrophy.

pomalidomide

Pomalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, pomalidomide is subsidised for the treatment of multiple myeloma.

ponatinib

Ponatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ponatinib is an agent subsidised for the treatment of:

• chronic myeloid leukaemia
• acute lymphoblastic leukaemia

ranibizumab

Ranibizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ranibizumab is subsidised for the treatment of:

• diabetic macular oedema
• retinal vein occlusion with macular oedema
• subfoveal choroidal neovascularisation due to:
• age related macular degeneration
• pathologic myopia
• other causes

ravulizumab

Ravulizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, ravulizumab is subsidised for the treatment of:

• paroxysmal nocturnal haemoglobinuria
• atypical haemolytic uraemic syndrome
• neuromyelitis optica spectrum disorder

riociguat

Riociguat is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, riociguat is subsidised for the treatment of:

• pulmonary arterial hypertension
• chronic thromboembolic pulmonary hypertension

ripretinib

Ripretinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ripretinib is subsidised for the treatment of gastrointestinal stromal tumour.

risankizumab

Risankizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, risankizumab is subsidised for the treatment of:

• severe psoriatic arthritis
• severe chronic plaque psoriasis:
• adult

risdiplam

Risdiplam is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, risdiplam is subsidised for the treatment of spinal muscular atrophy.

romiplostim

Romiplostim is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, romiplostim is subsidised for the treatment of idiopathic thrombocytopenic purpura.

ruxolitinib

Ruxolitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ruxolitinib is subsidised for the treatment of polycythemia vera.

secukinumab

Secukinumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, secukinumab is subsidised for the treatment of:

• ankylosing spondylitis
• hidradenitis suppurativa
• severe chronic plaque psoriasis:
• adult
• psoriatic arthritis
• non-radiographic axial spondyloarthritis

selexipag

Selexipag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, selexipag is subsidised for the treatment of pulmonary arterial hypertension.

selumetinib

Selumetinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, selumetinib is subsidised for the treatment of neurofibromatosis type 1.

sildenafil citrate

Sildenafil citrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, sildenafil citrate is subsidised for the treatment of pulmonary arterial hypertension.

somatrogon

Somatrogon is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, somatrogon is subsidised for the treatment of growth hormone deficiency (paediatric).

somatropin

Somatropin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, somatropin is subsidised for the treatment of growth hormone deficiency.

sonidegib

Sonidegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, sonidegib is subsidised for the treatment of basal cell carcinoma.

sunitinib malate

Sunitinib malate is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, sunitinib malate is subsidised for the treatment of malignant gastrointestinal stromal tumour.

tadalafil

Tadalafil is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, tadalafil is used to treat patients with pulmonary arterial hypertension.

tafamidis

Tafamidis is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, tafamidis is subsidised for the treatment of transthyretin amyloid cardiomyopathy.

teduglutide

Teduglutide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, teduglutide is subsidised for the treatment of short bowel syndrome with intestinal failure.

tezacaftor+ivacaftor

Tezacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, tezacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis.

tildrakizumab

Tildrakizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, tildrakizumab is subsidised for the treatment of:

• severe chronic plaque psoriasis:
• adult

tocilizumab

Tocilizumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through PBS Complex Drugs team.

Public and private hospital authority required (section 100 listing only).

Providing the patient meets specific restriction criteria, tocilizumab is subsidised for the treatment of:

• rheumatoid arthritis
• systemic juvenile idiopathic arthritis
• juvenile idiopathic arthritis
• giant cell arteritis

tofacitinib

Tofacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, tofacitinib is subsidised for the treatment of:

• ankylosing spondylitis
• juvenile idiopathic arthritis
• psoriatic arthritis
• rheumatoid arthritis
• ulcerative colitis:
• adult

trastuzumab

Trastuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, trastuzumab is subsidised for the treatment of:

• metastatic breast cancer
• early human epidermal growth factor receptor 2 positive breast cancer
• gastric cancer

trastuzumab emtansine

Trastuzumab emtansine is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, trastuzumab emtansine is subsidised for the treatment of:

• metastatic breast cancer
• early human epidermal growth factor receptor 2 positive breast cancer

upadacitinib

Upadacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, upadacitinib is subsidised for the treatment of:

• ankylosing spondylitis
• Crohn's disease:
• adult
• non-radiographic axial spondyloarthritis
• psoriatic arthritis
• rheumatoid arthritis
• ulcerative colitis:
• adult

ustekinumab

Ustekinumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, ustekinumab is subsidised for the treatment of:

• severe chronic plaque psoriasis
• psoriatic arthritis
• Crohn's disease:
• adult
• fistulising Crohn's disease
• ulcerative colitis:
• adult

vanzacaftor+tezacaftor+deutivacaftor

Vanzacaftor+tezacaftor+deutivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, vanzacaftor+tezacaftor+deutivacaftor is subsidised for the treatment of cystic fibrosis.

vedolizumab

Vedolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, vedolizumab is subsidised for the treatment of:

• Crohn's disease:
• adult
• chronic pouchitis
• ulcerative colitis:
• adult

vismodegib

Vismodegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, vismodegib is subsidised for the treatment of basal cell carcinoma.

vorinostat

Vorinostat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, vorinostat is subsidised for the treatment of cutaneous T-cell lymphoma.

vutrisiran

Vutrisiran is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority is required.

Providing the patient meets specific restriction criteria, vutrisiran is subsidised for the treatment of hereditary transthyretin amyloidosis.